Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

Publication Type:

Journal Article

Source:

The lancet oncology, Volume 11, Issue 6, p.543-52 (2010)

Keywords:

2010, Adolescent, Aminoglycosides, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Center-Authored Paper, Child, Child, Preschool, Clinical Research Division, Cytarabine, Cytogenetic Analysis, Daunorubicin, Disease-Free Survival, Etoposide, Female, Flow Cytometry Core Facility, Humans, Infant, Infant, Newborn, Leukemia, Myeloid, Acute, Male, Neoplasm, Residual, Remission Induction, Survival Rate, Young Adult

Abstract:

We sought to improve outcome in patients with childhood acute myeloid leukaemia (AML) by applying risk-directed therapy that was based on genetic abnormalities of the leukaemic cells and measurements of minimal residual disease (MRD) done by flow cytometry during treatment.